Cancer immunotherapy are classified as the latter with many anti-cancer benefits. Cancer immunotherapy is to reactivate or awaken the patient‘s immune system, therefore restores the ability of immune system to attack the tumor, and produces immune memory so that the tumor is not easy to recur. This mechanism does not rely on drugs direct killing of cancer cells. In cancer immunotherapy, tumor microenvironment regulators have the most potential for inducing excellent tumor response.
Read moreChidamide belongs to a new generation of epigenetic regulators and is a highly regarded new type of targeted cancer therapy that is mainly used for the treatment of solid tumors, lymphomas, and other hematopoietic tumors. Furthermore, its epigenetic regulation is a very promising mechanism that can be combined with endocrine drugs to reverse the drug resistance caused by the long-term use of endocrine inhibitors.
Read moreEpigenetic immunoactivators are a type of epigenetic modulators with strong immunoregulating activity, which can be used to treat cancers caused by uncontrolled epigenetic regulation, and are applied in cancer immunotherapy through effective immunoregulation of tumor microenvironment to achieve high tumor response rate. GNTbm-38 is a new oral small molecule drug and independently developed by GNTbm, and currently is under preclinical studies and will be filed for IND applications in US, Taiwan, and China.
GNTbm focuses on the R&D of epigenetic regulation, tumor microenvironment regulation, epigenetic immune regulation, and immunoregulatory multi-kinase inhibitors. The first step is to develop new indications for Tucidinostat simultaneously with international pharmaceutical companies; the second is independent R&D of tumor microenvironment regulators (TMRs); the third, independently developed epigenetic immunoactivator (GNTbm-38) ; and the fourth is the independent development of immunoregulatory multi-kinase inhibitor drugs (GNTbm-TKI).
Read more